Quite the study for Regenreron's dual spike-protein antibodies.
Integrated Phase 1 / Phase 2 / Phase 3 design
2,580 total patients, 39 sites now open.
Must not be confident of a big effect if they need that many patients.
(0)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-